出 生 年

1971

系/教研室

藥理

職    稱

教授

職    務

導師類型

博導

最高學歷/學位/畢業院校

博士

E-mail

Zhangduoduo2007@163.com

學科專業

藥理學

研究方向

代謝性疾病發病機制及藥物干預

人才稱號

三晉英才科技創新領軍人才，山西省學術技術帶頭人，山西省高等學校優秀青年學術帶頭人，山西省科教興晉突出貢獻專家

學術兼職

中國生物物理學會代謝生物學分會理事，山西省藥學會理事，山西省藥理學會理事，山西省生理學會理事，山西省醫師協會藥物及醫療器械臨床試驗專業委員會常務委員

學習工作經歷

教育經歷

(1) 2001.9–2004.7, c7c7.app, 生理學, 博士

(2) 1996.9–1999.7, c7c7.app, 藥理學, 碩士

(3) 1989.9–1994.7, c7c7.app, 臨床醫學, 學士

科研與學術工作經歷

(1)  1994-至今, c7c7.app，教師

(2) 2007.4-2010.7, Department of   Medicine, University of

Toronto, 博士后, 合作導師:   Herbert Gaisano

(3) 2004.11-2007.3, Department of   Physiology, University of

Toronto,   博士后, 合作導師: Michael Wheeler

主持的科研

/教學項目

1.    國家自然科學基金面上項目: Kv通道介導羅氟司特促進胰島素分泌和抑制β細胞凋亡雙重效應及其機制研究（81973378)，55萬，2020-2023，負責人。

2.    國家自然科學基金面上項目: AT1受體介導的胰島素分泌特點及機制研究（81670710)，55萬，2017-2020，負責人。

3.    國家自然科學基金面上項目:骨鈣素促胰島素分泌的離子通道調控機制研究（81273564)，45萬，2013-2016，負責人。

4.    國家自然科學基金面上項目：Kv通道介導P2Y受體調控的葡萄糖依賴性促胰島素分泌（81070662），36萬，2011-2013，負責人。

5.    山西省專利轉化專項計劃項目：一種小分子GLP-1R激動劑及其在代謝性疾病治療上的應用（202304016），10萬，2023.4-2024.3，負責人。

6.    中央引導地方科技發展資金：靶向GLP-1R的抗糖尿病減重創新藥物臨床前研究（YDZJSX2022A059），40萬，2022.7-2025.6，負責人。

7.    亞寶藥業集團股份有限公司橫向課題：YBHY012治療小細胞肺癌小鼠模型藥效學研究，12萬，2020，負責人。

8.    山西省高等學校優秀成果培育項目：嘌呤（P2Y）受體激動劑促胰島素分泌作用及機制研究（2019KJ022），5萬，2019-2021，負責人。

9.    西南醫科大學醫學電生理學重點實驗室開放基金：羅氟司特通過 KV 通道調控胰島素分泌和細胞凋亡的作用機制研究，5萬，2019-2021，負責人。

10. 亞寶藥業集團股份有限公司橫向課題：“降糖膠囊”糖尿病藥物干預實驗研究，15.9萬，2019，負責人。

11. 山西省回國留學人員科研資助項目：血管緊張素Ⅱ受體調控胰島素分泌及機制研究（2017-053），3萬，   2017.7-2020.7，負責人

12. 山西省留學回國人員科技活動項目擇優資助:骨鈣素對胰島功能的調控作用研究. （2016-97）5 萬, 2016-2018,負責人.

13. 山西省自然科學基金：嘌呤受體激動劑促胰島素分泌作用機制研究(2012011039-8)，5萬，2012-2014，負責人。

14. 山西省回國留學人員科研資助項目：P2Y受體激動劑促胰島素分泌的機制研究(2012-046)，6萬，2012-2014，負責人。

15. 山西省留學人員科技活動項目擇優資助：P2Y受體對胰島素分泌作用的調控機制研究(2011-762)，12萬，2011-2013，負責人。

16. 山西省高等學校優秀青年學術帶頭人(2011-24)，20萬，2011-2013，負責人。

代表性成果

（論文/專利/專著等）

SCI論文：

1.Guo C, Zhang Y, Xue H, Zhao X, Wang B, Deng L, Zhu X, Zhang   X, Zhang Y, Liu Y. Butein Alleviates Non-Alcoholic Steatohepatitis in   Leptin-Deficient Mice by Modulating the PDE4/cAMP/p-CREB Pathway. Drug Des   Devel Ther. 2025 Aug 14;19:7015-7031. doi: 10.2147/DDDT.S530855. PMID:   40831700; PMCID: PMC12360368.

2.Li Z, Wei H, Li R, Wu B, Xu M, Yang X, Zhang Y*, Liu Y*.   The effects of antihypertensive drugs on glucose metabolism. Diabetes Obes   Metab. 2024 Aug 14. doi: 10.1111/dom.15821. Epub ahead of print. PMID:   39140233.

3.Wu B, Li R, Hao J, Qi Y, Liu B, Wei H, Li Z, Zhang Y*, Liu   Y*. CT semi-quantitative score used as risk factor for hyponatremia in   patients with COVID-19: a cross-sectional study. Front Endocrinol (Lausanne).   2024 Jun 14;15:1342204. doi: 10.3389/fendo.2024.1342204. PMID: 38948513;   PMCID: PMC11211362.

4.Li M, Yang X, Li R, Wu B, Hao J, Qi Y, Bai T, Yang L, Zhang   Y*, Liu Y*. Visceral Fat Area and Subcutaneous Fat Area Increase in   Hyperthyroidism Patients After Treatment-A Single-Group Repeated-Measures   Trial. Diabetes Metab Syndr Obes. 2024 May 27;17:2165-2176. doi:   10.2147/DMSO.S458486. PMID: 38827164; PMCID: PMC11141577.

5.Han M, Cao X, Zhang J, Yang X, Zhang Y*, Liu Y*.   Association of Aldosterone, Renin, and Aldosterone to Renin Ratio with   Metabolic Profile in Primary Aldosteronism. Diabetes Metab Syndr Obes. 2024   May 18;17:2065-2074. doi: 10.2147/DMSO.S457243. PMID: 38778907; PMCID:   PMC11110821.

6.Li R, Wu B, Han M, Li M, Yang X, Zhang J, Zhang Y*, Liu Y*.   Uric Acid Metabolic Disorders in Pituitary-Target Gland Axis. Diabetes Metab   Syndr Obes. 2024 Feb 7;17:661-673. doi: 10.2147/DMSO.S448547. PMID: 38343584;   PMCID: PMC10859102.

7.Xu M, Hao J, Qi Y, Wu B, Li R, Yang X, Zhang Y*, Liu Y*.   Causal effects of gut microbiota on diabetic neuropathy: a two-sample   Mendelian randomization study. Front Endocrinol (Lausanne). 2024 Aug   2;15:1388927. doi: 10.3389/fendo.2024.1388927. PMID: 39157679; PMCID:   PMC11329939.

8.Wang R, Chen K, Liu S, Ren R, Hou H, Zeng Q, Zhang Y*, Liu   Y*. Design, synthesis and biological evaluation of novel oxazole derivatives   as potential hypoglycemic agents. Bioorg Med Chem. 2024 Nov 15;114:117961.   doi: 10.1016/j.bmc.2024.117961. Epub 2024 Oct 18. PMID: 39437535.

9.Ruifeng Wang, Xin Zhao, Hongbao Hou, Ke Chen, Shuihua Liu,   Ruyue Ren, Yunfeng Liu*, Yi Zhang*.    Cutting-Edge   FAK-targeting PROTACs: design, synthesis, and biological Evaluation. Journal of Chinese Pharmaceutical Sciences. 2024, Vol. 33:Issue (9):   767-782.DOI: 10.5246/jcps.2024.09.057

10.   Jiao JJ, Hu Y, Cui YJ, Tuo CM, Wang YX, Li XY, Zhang Y, Wu   MN. Anisomycin alleviates cognitive impairments and pathological features in   3xTg-AD mice. Neuropharmacology. 2024 Sep 18:110159. doi:   10.1016/j.neuropharm.2024.110159. Epub ahead of print. PMID: 39303856.

11.   Zhang X, Shi X, Zhang X, Zhang Y, Yu S, Zhang Y, Liu Y.   Repositioning fluphenazine as a cuproptosis-dependent anti-breast cancer drug   candidate based on TCGA database. Biomed Pharmacother. 2024 Sep;178:117293.   doi: 10.1016/j.biopha.2024.117293. Epub 2024 Aug 13. PMID: 39142251.

12.   Zhao X, Zeng Q, Yu S, Zhu X, Bin Hu, Deng L, Zhang Y, Liu   Y. GLP-1R mediates idebenone-reduced blood glucose in mice. Biomed   Pharmacother. 2024 Sep;178:117202. doi: 10.1016/j.biopha.2024.117202. Epub   2024 Jul 24. PMID: 39053424.

13.   Wang B, Zhu X, Yu S, Xue H, Deng L, Zhang Y, Zhang Y, Liu   Y. Roflumilast ameliorates GAN diet-induced non-alcoholic fatty liver disease   by reducing hepatic steatosis and fibrosis in ob/ob mice. Biochem Biophys Res   Commun. 2024 Aug 30;722:150170. doi: 10.1016/j.bbrc.2024.150170. Epub 2024   May 23. PMID: 38797152.

14.   Li M, Zhang J, Yang G, Zhang J, Han M, Zhang Y, Liu Y.   Effects of sodium-glucose cotransporter 2 inhibitors on renal risk factors in   patients with abnormal glucose metabolism: a meta-analysis of randomized   controlled trials. Eur J Clin Pharmacol. 2023 Jun;79(6):859-871. doi:   10.1007/s00228-023-03490-8. Epub 2023 Apr 25. PMID: 37097298.

15.   Zhang J, Li   MN, Yang GM, Hou XT, Yang D, Han MM, Zhang Y, Liu YF. Effects of water-sodium   balance and regulation of electrolytes associated with antidiabetic drugs.   Eur Rev Med Pharmacol Sci. 2023 Jun;27(12):5784-5794. doi:   10.26355/eurrev_202306_32817. PMID: 37401315.

16.   Li M, Liu   Z, Yang X, Zhang J, Han M, Zhang Y, Liu Y. The effect of sodium-glucose   cotransporter 2 inhibitors as an adjunct to insulin in patients with type 1   diabetes assessed by continuous glucose monitoring: A systematic review and   meta-analysis. J Diabetes Complications. 2023 Dec;37(12):108632. doi:   10.1016/j.jdiacomp.2023.108632. Epub 2023 Oct 21. PMID: 37907042.

17.   Xue H, Xing   HJ, Wang B, Fu C, Zhang YS, Qiao X, Guo C, Zhang XL, Hu B, Zhao X, Deng LJ,   Zhu XC, Zhang Y, Liu YF. Cinchonine, a Potential Oral Small-Molecule   Glucagon-Like Peptide-1 Receptor Agonist, Lowers Blood Glucose and   Ameliorates Non-Alcoholic Steatohepatitis. Drug Des Devel Ther. 2023 May   11;17:1417-1432. doi: 10.2147/DDDT.S404055. PMID: 37197367; PMCID:   PMC10184894.

18.   Li M, Zhang   J, Yang G, Zhang J, Han M, Zhang Y, Liu Y. Effects of Anterior Pituitary   Adenomas' Hormones on Glucose Metabolism and Its Clinical Implications.   Diabetes Metab Syndr Obes. 2023 Feb 13;16:409-424. doi: 10.2147/DMSO.S397445.   PMID: 36816815; PMCID: PMC9937076.

19.   Zhao   X, Deng L, Ren L, Yang H, Wang B, Zhu X, Zhang X, Guo C, Zhang Y, Liu Y.   VPAC2 receptor mediates VIP-potentiated insulin secretion via ion channels in   rat pancreatic β cells. Exp Cell Res. 2023 Feb 15;423(2):113471. doi:   10.1016/j.yexcr.2023.113471. Epub 2023 Jan 13. PMID: 36642263.

20.   Dan Yang, Xintong Hou, Guimei Yang, Mengnan Li, Jian Zhang, Minmin Han, Yi Zhang, Yunfeng Liu. Effects of   the POMC System on Glucose Homeostasis and Potential Therapeutic Targets for   Obesity and Diabetes. Diabetes Metabolic Syndrome and   Obesity-Targets and Therapy. 2022 Sep 25;15:2939-2950.doi:   10.2147/DMSO.S380577

21.   Xintong Hou, Dan Yang, Guimei Yang, Mengnan Li, Jian Zhang, Jiaxin Zhang, Yi Zhang, Yunfeng Liu. Therapeutic   potential of vasoactive intestinal peptide and its receptor VPAC2 in type 2   diabetes.Frontiers in Endocrinology. 2022 Sep 20;13:984198.doi:   10.3389/fendo.2022.984198.

22.   Zhao X, Cui   L, Zhang Y, Guo C, Deng L, Wen Z, Lu Z, Shi X, Xing H, Liu Y, Zhang Y. Screening for Potential Therapeutic Agents for   Non-Small Cell Lung Cancer by Targeting Ferroptosis.Front Mol   Biosci. 2022 Jul 14;9:917602. doi: 10.3389/fmolb.2022.917602. eCollection   2022.（2區）

23.   Tao Liu , Lijuan Cui, Huan Xue, Xiaohua Yang, Mengmeng Liu, Linping Zhi, Huanhuan Yang, Zhihong Liu, Min Zhang, Qing Guo, Peifeng He, Yunfeng Liu, Yi Zhang. Telmisartan   Potentiates Insulin Secretion via Ion Channels, Independent of the AT1   Receptor and PPARγ. Front Pharmacol . 2021 Sep 14;12:739637. doi:   10.3389/fphar.2021.739637. eCollection 2021.（2區）

24.   Xin   Zhao, Minghe Wang, Lijuan Cui, Chao   Fu, Zhihong Lu, Zhitong Wen, Huan Xue, Yunfeng Liu* and Yi Zhang*. GLP-1 Receptor Agonists: Beyond Its   Pancreatic Effects. Front Endocrinol (Lausanne). 2021 Aug   23;12:721135. doi: 10.3389/fendo.2021.721135. eCollection 2021（2區）

25.   Zhihong Liu，Huanhuan   Yang，Linping Zhi，Huan Xue，Zhihong Lu，Yanli Zhao，Lijuan Cui，Tao Liu，Shouan Ren，Peifeng He，Yunfeng Liu   and Yi Zhang*. Sphingosine   1-phosphate stimulates insulin secretion and improves cell survival by   blocking voltage-dependent K + channels in β cells.Frontiers in Pharmacology,   2021. 12：683674.  doi: 10.3389/fphar.2021.683674（2區）

26.   Xiaohua   Yang, Min Zhang, Zhihong Lu, Linping Zhi, Huan Xue, Tao Liu, Mengmeng Liu,   Lijuan Cui, Zhihong Liu, Peifeng He, Yunfeng Liu* and Yi Zhang*. Novel Small   Molecule Glucagon-Like Peptide-1 Receptor Agonist S6 Stimulates Insulin   Secretion From Rat Islets. Frontiers in Pharmacology, 2021 Apr 29; 12:664802. doi:   10.3389/fphar.2021.664802. eCollection 2021.（2區）

27.   Lijuan Cui, Huan Xue, Zhitong Wen, Zhihong Lu, Yunfeng Liu, Yi Zhang^*. Prognostic   roles of metabolic reprogramming-associated genes in patients with   hepatocellular carcinoma. Aging, 2020 Nov 12;12(21):22199-22219. doi: 10.18632/aging.104122. Epub 2020 Nov 12.（1區）

28.  T. BAI, H. YANG, H.   WANG, L. ZHI, T. LIU, L. CUI, W. Liu, Y. Wang, M. ZHANG, Y. Liu and Y. ZHANG^*,   Inhibition of voltage-gated K+ channels mediates docosahexaenoic   acid-stimulated insulin secretion in rat pancreatic β-cells.[J] . Food &   Function, 2020, DOI:10.1039/D0FO01891K.（1區）

29.   Minmin Han,   Xiaoming Cao, Changjian Zhao, Luyang Yang, Nan Yin, Pengliang Shen, Jin Zhang,   Fei Gao, Yi Ren, Dong Liang, Jing Yang, Yi Zhang^* and Yunfeng Liu^*.   Assessment of Glycometabolism Impairment and Glucose Variability Using Flash   Glucose Monitoring System in Patients With Adrenal Diseases. Front Endocrinol   (Lausanne). 2020 September;11 doi: 10.3389/fendo.2020.544752（2區）

30.  Cui LJ, Bai T, Zhi LP,   Liu ZH, Liu T, Xue H, Yang HH, Yang XH, Zhang M, Niu YR, Liu YF, Zhang Y^*.   Analysis of long noncoding RNA-associated competing endogenous RNA network in   glucagon-like peptide-1 receptor agonist-mediated protection in β cells.   World J Diabetes 2020; 11(9): 374-390

31.   Mengmeng Liu, Lele Ren, Xiangqin Zhong, Yaqin Ding, Tao Liu, Zhihong Liu, Xiaohua Yang, Lijuan Cui, Lijun Yang, Yanying Fan, Yunfeng Liu, Yi Zhang* . D2-Like   Receptors Mediate Dopamine-Inhibited Insulin Secretion via Ion Channels in   Rat Pancreatic β-Cells. Front Endocrinol (Lausanne). 2020 Apr   7;11:152. (通訊作者)2區，3.644

32.   Liu M, Yang X,   Bai T, Liu Z, Liu T, Wang Y, Cui L, Liu Y, Zhang Y*. PACAP stimulates insulin secretion by PAC1 receptor and   ion channels in β-cells. Cell Signal. 2019 Sep;61:48-56. (通訊作者)2區，3.388

33.   Liu Y,  Zhong X,   Ding Y, Ren L, Bai T, Liu M, Liu Z, Guo Y, Guo Q, Zhang Y, Yang J, Zhang Y*. Inhibition of voltage-dependent potassium   channels mediates cAMP-potentiated insulin secretion in rat pancreatic   β cells. Islets. 2017 Mar 4;9(2):11-18. (通訊作者). 4區，1.879

34.   Gao J, Bai T, Ren L, Ding Y, Zhong X, Wang H, Guo Y, Li J, Liu Y, Zhang Y*,  The PLC/PKC/Ras/MEK/Kv channel pathway is involved in uncarboxylated osteocalcin-regulated insulin secretion in rats.   Peptides. 2016   Dec;86:72-79. (通訊作者) 3區，2.659

35.   Zhang Y*, Ding Y, Zhong X, Guo Q, Wang H, Gao J, Bai T, Ren L, Guo Y, Jiao X, Liu Y. Geniposide acutely stimulates insulin secretion in pancreatic β-cells   by regulating GLP-1 receptor/cAMP signaling and ion channels. Mol Cell Endocrinol. 2016 Jul   15;430:89-96. (通訊作者)2區，3.693

36.   Gao J, Zhong X, Ding Y, Bai T, Wang H, Wu H, Liu Y, Yang J, Zhang Y*. Inhibition of   voltage-gated potassium channels mediates uncarboxylated   osteocalcin-regulated insulin secretion in rat pancreatic β cells. Eur J Pharmacol. 2016 Apr   15;777:41-8.(通訊作者)3區，3.17

37.   Zhang Y*, Wang   H, Guo Q, Li X, Gao J, Liu Y, Yang C, Niu L, Yang J. PI3K is involved   in P2Y receptor-regulated cAMP   /Epac/Kv channel signaling pathway in pancreatic β cells.   Biochem Biophys Res Commun. 2015 Oct 2;465(4):714-8. (通訊作者)3區，2.705

38.   Zhang Y*, Guo   Q, Li X, Gao J, Liu Y, Yang J, Li Q. P2Y purinergic receptor-regulated insulin   secretion is mediated by a cAMP/Epac/Kv channelpathway.   Biochem Biophys Res Commun. 2015 May 8;460(3):850-6. （通訊作者)3區，2.705

39.   Li X, Guo Q,   Gao J, Yang J, Zhang W, Liang Y, Wu D, Liu Y*, Weng J, Li Q, Zhang Y*. The   adenylyl cyclase inhibitor MDL-12,330A potentiates insulin secretion via   blockade of voltage-dependent K+ channels in pancreatic beta cells. PLOS one.   8(10):e77934.2013 （通訊作者）3區，2.776

40.   Liu Y*, Zhang   Y*, Zhu D*, Gaisano HY. VAMP8 Deletion Delays the Onset of   Streptozotocin-Induced Hyperglycemia. Can J Diabetes.   36 (2012) 251e256（*共同第一作者）4區，2.887

41.   Zhu D*,   Zhang Y*, Lam PP*, Dolai S*, Liu Y*, Cai EP, Choi D, Schroer SA, Kang Y,   Allister EM, Qin T, Wheeler MB, Wang CC, Hong WJ, Woo M, Gaisano HY.Dual Role of VAMP8 in Regulating Insulin Exocytosis and   Islet β Cell Growth. Cell Metab. 2012 Aug   8;16(2):238-49.   （*共同第一作者）top 1區，22.415

42.   Kang Y*,   Zhang Y*, Liang T*, Leung YM, Ng B, Xie H, Chang N, Chan J, Shyng SL,   Tsushima R, Gaisano HY. ATP modulates interaction of syntaxin-1A with   sulfonylurea receptor 1 to regulate pancreatic beta-cell KATP channels. J   Biol Chem. 2011 Feb 18;286(7):5876-83.（*共同第一作者）   2區，4.106

43.   Zhang Y,   Kang Y, Lam PPL, Chang N, Liu Y, Olkkonen VM, Gaisano HY. Cab45b, a Munc18b   Interacting-Partner, Regulates Exocytosis in Pancreatic Beta Cells. J Biol   Chem.  2009 Jul 31;284(31):20840-7，（第一作者）2區，4.106

44.   Zhang Y*, Liu   Y*, Qu J, Zhang N, Diao J, Strijbos P, Tsushima R, Robinson RB, Gaisano HY,   Wang Q, Wheeler MB. Functional Characterization of HCN Channels in   Rat Pancreatic β Cells. Journal   of Endocrinology 2009 Oct;203(1):45-53， (通訊作者) 2區，4.381

45.   Zhang Y, Zhang   N, Gyulkhandanyan AV, Xu E, Gaisano HY, Wheeler MB, Wang Q. Presence of   functional hyperpolarisation-activated cyclic nucleotide-gated channels in   clonal alpha cell lines and rat islet alpha cells. Diabetologia. 2008   Dec;51(12):2290-8.（第一作者）2區，7.113

46.  Xu E*, Kumar M*, Zhang   Y, Ju W, Obata T, Zhang N, Liu S, Wendt A, Deng S, Ebian Y, Wheeler MB, Braun   M, Wang Q. Intra-islet insulin suppresses glucagon release via GABA-GABAA   receptor system. Cell Metabolism 2006; 3(1):47-58    （第二作者） top 1區，22.415

發明專利：

1.   日本專利：アニンマイシソ誘導體、アニンマイシソ及びその誘導體をG L P-1R作動薬としての使用方法，特許第７５６６３７８號；授權日期：2024.10.04

2.   一種GLP-1R激動劑。專利號：ZL 2023 1 0498208.X；授權日期：2025.02.11

3.   一種式(I)化合物制備鎮痛藥物中的用途。專利號：ZL 2022 1 0884726.0； 授權日期：2023.11.17  

4.   一種化合物在制備治療阿爾茲海默癥藥物中的用途。專利號：ZL 2022 1 0884725.6；授權公告日：2024. 02. 02

5.   一種用于非酒精性脂肪肝病的化合物、組合物及其用途。專   利 號：ZL 2022 1 0878875.6 授權日期：2023年08月25日

6.   一種茴香霉素衍生物以及茴香霉素和其衍生物作為GLP-1R激動劑的用途。專利號：ZL 2021 1 0103556.3；授權日期：2023年05月30日

7.   一種小分子GLP-1R激動劑及其應用。專利號：ZL 2020 1 0498224.5。授權日期：2021.4.23

8.   國家發明專利：一種小分子GLP-1R激動劑及其應用。授權號：ZL 2020 1 0498224.5。授權日期：2021.4.23  （第一發明人）

9.   一種治療乳腺癌的藥物組合物。專 利 號：ZL 2023 1 0041357.3； 授權日期：2025年03月14日

10. 一種便于控制注射量的胰島素注射筆。授權號：ZL   2020 2 2755790.8；授權日期：2021.12.28

獲獎及個人榮譽

1.    第十一屆全國大學生醫學創新大賽暨2025“一帶一路”國際醫學創新競賽銅獎

2.    第二屆山西省博士后創新大賽金獎

3.    第十三屆中國創新創業大賽山西賽區二等獎

4.    2023山西省留學人員創新創業大賽第2名

5.    2022深圳南山創新創業大賽生物醫藥行業賽第2名

6.    三晉英才科技創新領軍人才

7.    山西省學術技術帶頭人

8.    山西省科技進步獎二等獎（2023,2021）

9.    山西省高等學校優秀成果科技進步二等獎

10. 山西省高等學校優秀青年學術帶頭人

11. 山西省科教興晉突出貢獻專家

研究生培養

培養的研究生多次獲得國家獎學金